Pulmonary Tuberculosis Reactivation and CNS Involvement Following Treatment of Myelofibrosis with Ruxolitinib: Case Report and Review of the Literature of Incidence in Myeloproliferative Neoplasms

Author Details

Laura Finn, Jessica Foy, Evan Dvorin

Journal Details

Published

Published: 25 November 2020 | Article Type :

Abstract

A 69-year-old man with primary myelofibrosis was being treated with ruxolitinib for worsening constitutional symptoms. While ruxolitinib provided rapid symptom relief, he developed hemoptysis and changes to chest imaging. Comprehensive evaluation was diagnostic of mycobacterium tuberculosis with eventual progression to the central nervous system. Here we report the successful treatment of tuberculosis reactivation and describe the incidence of mycobacterium tuberculosis infection during treatment with ruxolitinib. Clinicians should consider risk of opportunistic infections when treating patients with myeloproliferative neoplasms with immunosuppressant medications such as ruxolitinib.

Keywords: myelofibrosis, myeloproliferative neoplasm, mycobacterium tuberculosis, ruxolitinib.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © Author(s) retain the copyright of this article.

Statistics

213 Views

326 Downloads

Volume & Issue

Article Type

How to Cite

Citation:

Laura Finn, Jessica Foy, Evan Dvorin. (2020-11-25). "Pulmonary Tuberculosis Reactivation and CNS Involvement Following Treatment of Myelofibrosis with Ruxolitinib: Case Report and Review of the Literature of Incidence in Myeloproliferative Neoplasms." *Volume 3*, 2, 11-16